Tackling multi-drug resistant fungi by efflux pump inhibitors

• Published in: Biochemical pharmacology Vol. 226; p. 116400
• Main Authors: Engle, Kritika, Kumar, Gautam
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01-08-2024
• Subjects: Animals; Antifungal; Antifungal Agents - pharmacology; ATP-binding cassette; Azoles; Drug Resistance, Multiple, Fungal; Echinocandins; Efflux pump; Fungi - drug effects; Fungi - metabolism; Humans; Major facilitator’s families; Membrane Transport Proteins - metabolism; Mycoses - drug therapy; Mycoses - microbiology; Natural products; Polyenes; Repurposable drugs; RNA; ARPE-19; NGLY1; HBE; PVP; AUC; ENMs; NBD; Repurposable drugs; MDR; XBD; HGF-1; R6G; MIC; IR; MEC; PDREs; PBMC; RCE; ZOI; CaCdr2p; ROS; ATP-binding cassette; UPRT; Efflux pump; ABC; Antifungal; CFE; Ag-NPs; Major facilitator’s families; FICI; MRP; MFC; 5-FC; IFI; CCBs; CgCdr1p; CaCdr1p; Polyenes; SLNs; HUVEC; MFS; Cdr2; Cdr1; PDR; HSP90; TMD; PPIs; NPs; NAC; Azoles; NMR; PAF; Natural products; DNA; FLZ-SLNs; Echinocandins; TEM; HaCaT
• ISSN: 0006-2952; 1873-2968; 1873-2968
• DOI: 10.1016/j.bcp.2024.116400

[Display omitted]
The emergence of multidrug-resistant fungi is of grave concern, and its infections are responsible for significant deaths among immunocompromised patients. The treatment of fungal infections primarily relies on a clinical class of antibiotics, including azoles, polyenes, echinocandins, polyketides, and a nucleotide analogue. However, the incidence of fungal infections is increasing as the treatment for human and plant fungal infections overlaps with antifungal drugs. The need for new antifungal agents acting on different targets than known targets is undeniable. Also, the pace at which loss of fungal susceptibility to antibiotics cannot be undermined. There are several modes by which fungi can develop resistance to antibiotics, including reduced drug uptake, drug target alteration, and a reduction in the cellular concentration of the drug due to active extrusions and biofilm formation. The efflux pump’s overexpression in the fungi primarily reduced the antibiotic’s concentration to a sub-lethal concentration, thus responsible for developing resistant fungus strains. Several strategies are used to check antibiotic resistance in multi-drug resistant fungi, including synthesizing antibiotic analogs and giving antibiotics in combination therapies. Among them, the efflux pump protein inhibitors are considered potential adjuvants to antibiotics and can block the efflux of antibiotics by inhibiting efflux pump protein transporters. Moreover, it can sensitize the antifungal drugs to multi-drug resistant fungi with overexpressed efflux pump proteins. This review discusses the natural lead molecules, repurposable drugs, and formulation strategies to overcome the efflux pump activity in the fungi.